pyxisoncology.com Open in urlscan Pro
174.138.63.182  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
 * Careers
 * Contact

 * AboutMenu Toggle
   * Overview
   * Leadership
   * Partners
 * Our ApproachMenu Toggle
   * ADC Landscape
   * IO Landscape
 * PortfolioMenu Toggle
   * A Novel Pipeline
   * ADCs
   * Immuno-oncology
 * InvestorsMenu Toggle
   * News releases
   * Events & presentations
   * Corporate governanceMenu Toggle
     * Governance Overview
     * Board of Directors
     * Management Team
     * Committee composition
   * Financial InformationMenu Toggle
     * SEC filings
   * Stock InformationMenu Toggle
     * Stock quote & chart
   * SHAREHOLDER SERVICESMenu Toggle
     * Investor FAQs
     * Email alerts
     * RSS feeds


Main Menu
 * AboutMenu Toggle
   * Overview
   * Leadership
   * Partners
 * Our ApproachMenu Toggle
   * ADC Landscape
   * IO Landscape
 * PortfolioMenu Toggle
   * A Novel Pipeline
   * ADCs
   * Immuno-oncology
 * InvestorsMenu Toggle
   * News releases
   * Events & presentations
   * Corporate governanceMenu Toggle
     * Governance Overview
     * Board of Directors
     * Management Team
     * Committee composition
   * Financial InformationMenu Toggle
     * SEC filings
   * Stock InformationMenu Toggle
     * Stock quote & chart
   * SHAREHOLDER SERVICESMenu Toggle
     * Investor FAQs
     * Email alerts
     * RSS feeds

 * Careers
 * Contact


CHARTING A COURSE TO THERAPEUTICS FOR DIFFICULT-TO-TREAT CANCERS


OUR GUIDING PRINCIPLE

Pyxis Oncology has assembled a differentiated portfolio of potent biologics,
including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb)
immunotherapies, with the potential to further improve outcomes for patients
with cancer.

About Us



A DIFFERENTIATED PORTFOLIO


ANTIBODY-DRUG CONJUGATES (ADCS)

ADCs deliver potent cancer-killing agents directly to tumor cells. Our
technology platform is designed to enable us to develop safer and more effective
ADCs. 

Learn More About ADCs


IMMUNO-ONCOLOGY (IO)

IO approaches mobilize the body’s immune system to attack cancer cells. Our
immunotherapies may block cancer’s defense mechanisms and activate components of
the immune system to overcome immune suppression.

Learn More About (IO)


OUR PIPELINE



We are focused on developing an arsenal of next-generation therapeutics to
target difficult-to-treat cancers and improve the quality of life of patients.
We have built a broad portfolio of novel ADC and mAb product candidates that we
are developing as monotherapies and in combination with other therapies.

Explore Our Pipeline



RECENT NEWS

December 01, 2022


PYXIS ONCOLOGY ANNOUNCES FDA CLEARANCE OF TWO IND APPLICATIONS

November 01, 2022


PYXIS ONCOLOGY REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30,
2022 AND PROVIDES CORPORATE UPDATE

September 30, 2022


PYXIS ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Read All News


JOIN US

If you share our passion for charting a course to develop therapeutics for
patients with difficult-to-treat cancers and want to contribute to our vision,
join us!

Apply Now


150 Cambridgepark Drive
8th Floor, Suite 2
Cambridge, MA 02140
(617) 453-3596 | info@pyxisoncology.com

Twitter Linkedin-in
 * Copyright © 2022 Pyxis Oncology
 * Privacy Policy
 * Accessibility